BioCentury
ARTICLE | Product Development

HBV test kitchen

How far industry is from assembling a functional cure in HBV

August 12, 2017 12:42 AM UTC
The pharma also has an early stage preclinical therapeutic vaccine program that delivers HBV DNA plasmid through the skin via electroporation.

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the virus that persist on standard of care.

Data on combinations that add a single MOA to standard of care will begin to read out over the next 18 months. More complex combinations, including cocktails combining novel mechanisms, are a few years away...